安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Compass Pathways | Biotechnology Company
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health We are studying investigational psilocybin treatment in treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa
- Compass psychedelic therapy wins phase 3, investors unimpressed
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed The study
- Compass Pathways’ Psilocybin Drug Hits Primary Goal in . . .
Compass Pathways says a single dose of its synthetic psilocybin significantly reduced depression symptoms in patients who haven’t responded to standard treatments, marking a key milestone in what could become the first FDA-approved psychedelic therapy for treatment-resistant depression The company announced that its lead candidate, COMP360, met the primary endpoint in its Phase 3 COMP005
- Compass Pathways - Investor Relations
We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments
- Compass Pathways psilocybin depression trial meets goal - STAT
Compass Pathways said Monday it achieved its primary endpoint in an early Phase 3 readout from the largest-ever study of psilocybin for treatment-resistant depression Yet its stock price fell 36%
- Compass Pathways depression drug succeeds late-stage trial
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study
- Compass Pathways - Wikipedia
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines [1] [2] [3] Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression
|
|
|